Regen BioPharma Inc
OTC:RGBP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Ahmad Zaki Resources Bhd
KLSE:AZRB
|
MY |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
CN |
|
S
|
Solid Stone Co Ltd
BSE:513699
|
IN |
|
Arena Bilgisayar Sanayi ve Ticaret AS
IST:ARENA.E
|
TR |
|
A
|
Aluminum Corp of China Ltd
OTC:ALMMF
|
CN |
|
Enwave Corp
XTSX:ENW
|
CA |
|
Logitech International SA
SIX:LOGN
|
CH |
|
Telesis Bio Inc
NASDAQ:TBIO
|
US |
|
Silverlake Axis Ltd (Pre Reincorporation)
SGX:5CP
|
MY |
|
Chain Bridge I
NASDAQ:CBRG
|
US |
|
A
|
Anand Rathi Wealth Ltd
NSE:ANANDRATHI
|
IN |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Regen BioPharma Inc
OTC:RGBP
|
77.7k USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
580.2B USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.4B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Regen BioPharma Inc
Glance View
Regen Biopharma, Inc. is a biotechnology company, which focuses on the immunology and immunotherapy space. The company is headquartered in La Mesa, California and currently employs 1 full-time employees. The company went IPO on 2014-09-03. The firm is focused on immuno-oncology, stem cell/cancer stem cell, and gene silencing. The company is engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The firm focuses on the treatment of hematopoiesis (blood formation), breast cancer, liver cancer, leukemia, myelodysplastic syndrome, and aplastic anemia. The firm is also engaged in developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating molecular processes in cancer stem cell through its molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Regen BioPharma Inc is -729.9%, which is below its 3-year median of 2 139.2%.
Over the last 3 years, Regen BioPharma Inc’s Net Margin has decreased from 520.8% to -729.9%. During this period, it reached a low of -729.9% on Jan 1, 2026 and a high of 28 454.2% on Mar 31, 2023.
